Search Result

Pathways Recommended:	Neuronal Signaling JAK/STAT Signaling

Results for "

signalling inhibition

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (2) Androgen Receptor (1) Antibiotic (1) AP-1 (1) APC (1) Apoptosis (14) ATM/ATR (1) Autophagy (6) Bacterial (2) Bcl-2 Family (1) Btk (7) c-Myc (1) Casein Kinase (3) COX (2) E1/E2/E3 Enzyme (1) ERK (3) Farnesyl Transferase (1) Free Fatty Acid Receptor (1) Guanylate Cyclase (2) HIV (2) IKK (2) Influenza Virus (2) Interleukin Related (2) JAK (5) Keap1-Nrf2 (1) Kinesin (1) MAGL (1) MDM-2/p53 (1) Microtubule/Tubulin (4) Monoamine Oxidase (2) NF-κB (11) NO Synthase (3) Notch (2) P2X Receptor (1) P2Y Receptor (1) p38 MAPK (3) PAI-1 (1) Parasite (3) PARP (2) PD-1/PD-L1 (1) PDGFR (1) Phosphatase (4) Phosphodiesterase (PDE) (1) Phospholipase (1) PI3K (2) PROTACs (2) Ras (3) Ribosomal S6 Kinase (RSK) (1) SHP2 (1) Smo (4) STAT (3) STING (1) Survivin (1) TGF-beta/Smad (2) TGF-β Receptor (3) TNF Receptor (1) Toll-like Receptor (TLR) (2) ULK (1) Wnt (4) β-catenin (4) γ-secretase (3)
By Research Areas:	Cancer (55) Cardiovascular Disease (3) Infection (8) Inflammation/Immunology (26) Metabolic Disease (6) Neurological Disease (7)
Click Chemistry:	Alkynes (2)

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Peptides

Inhibitory Antibodies

Natural
Products

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N2312

Mogrol 1 Publications Verification	ERK STAT	Cancer
Mogrol is a biometabolite of mogrosides, and acts via inhibition of the ERK1/2 and STAT3 pathways, or reducing CREB activation and activating AMPK signaling.

HY-N6940

Prosapogenin A Progenin III	Apoptosis	Cancer
Prosapogenin A, a natural product from Veratrum, induces apoptosis in human cancer cells in vitro via inhibition of the STAT3 signaling pathway and glycolysis .

HY-131502

Taspine	P2X Receptor	Inflammation/Immunology
Taspine is a natural product with anti-inflammatory activity. Taspine suppresses P2X4 receptor activity via PI3K inhibition. Taspine inhibits pro-inflammatory signalling via inhibition of P2X4 receptors in macrophage .

HY-N1469

Kaurenoic acid
Kaurenoic acid is a diterpene from Sphagneticola trilobata, inhibits Inflammatory Pain by the inhibition of cytokine production and activation of the NO–cyclic GMP–PKG–ATP-sensitive potassium channel signaling pathway .

HY-156512

DT-6	TGF-beta/Smad	Cancer
DT-6 is an effective TGF-β1 inhibitor. DT-6 inhibits M2 macrophage induced epithelial to mesenchymal transition and invasive migration of cancer cells. DT-6 can be used for cancer diseases research .

HY-N6673

Okanin 1 Publications Verification	Toll-like Receptor (TLR) NF-κB	Cardiovascular Disease Neurological Disease Inflammation/Immunology
Okanin, effective constituent of the flower tea Coreopsis tinctoria, attenuates LPS-induced microglial activation through inhibition of the TLR4/NF-κB signaling pathways .

HY-121418

Lusianthridin	c-Myc	Cancer
Lusianthridin, a pure compound from Dendrobium venustum, have an anti-migratory effect. Lusianthridin enhances c-Myc degradation through the inhibition of Src-STAT3 signaling .

HY-P5819A

xStAx-VHLL TFA	PROTACs β-catenin	Cancer
xStAx-VHLL TFA, a PROTAC, sustains β-catenin degradation and manifested strong inhibition of Wnt signaling. xStAx-VHLL TFA promotes β-catenin ubiquitination .

HY-N0635

Prim-O-glucosylcimifugin 2 Publications Verification	NO Synthase COX	Inflammation/Immunology
Prim-O-glucosylcimifugin exerts anti-inflammatory effects through the inhibition of iNOS and COX-2 expression by through regulating JAK2/STAT3 signaling.

HY-141523

Vociprotafib RMC-4630; SHP2-IN-7	SHP2 Phosphatase	Cancer
Vociprotafib (RMC-4630) is a SHP2 inhibitor, a phosphatase whose inhibition blocks activation of the RAS-RAF-MEK-ERK signaling pathway. Vociprotafib has antitumor activity .

HY-132808

Atuzabrutinib SAR 444727; PRN473	Btk	Inflammation/Immunology
Atuzabrutinib (SAR 444727) is a potent, selective reversible inhibitor of Btk (Bruton's tyrosine kinase) inhibitor. Atuzabrutinib inhibits neutrophil recruitment via inhibition of macrophage antigen-1 signalling .

HY-18614

LY900009	Notch γ-secretase	Cancer
LY900009 is a potent and orally active, First-in-class inhibitor of Notch signaling via selective inhibition of the γ-secretase protein (GSI). LY900009 inhibited Notch signalling in tumor cell lines and endothelial cells (IC₅₀ range: 0.005-20 nM). LY900009 can be used for advanced cancer research .

HY-N2477

Taraxerol	Apoptosis NF-κB	Inflammation/Immunology Cancer
Taraxerol is isolated from Taraxacum mongolicum, and has anti-inflammtory and anti-cancer effects. Taraxerol attenuates acute inlammation through inhibition of NF-κB signaling pathway. Taraxerol induces cell apoptosis .

HY-N2357

Eudesmin (-)-Eudesmin; Eudesmine; (-)-Eudesmine	Ribosomal S6 Kinase (RSK)	Infection Metabolic Disease Inflammation/Immunology Cancer
Eudesmin ((-)-Eudesmin) impairs adipogenic differentiation via inhibition of S6K1 signaling pathway. Eudesmin possesses diverse therapeutic effects, including anti-tumor, anti-inflammatory, and anti-bacterial activities .

HY-12848

SAG Maximum Cited Publications 18 Publications Verification	Smo	Cancer
SAG is a potent Smoothened (Smo) receptor agonist (EC₅₀=3 nM; K_d=59 nM). SAG activates the Hedgehog signaling pathway and counteracts Cyclopamine (HY-17024) inhibition of Smo .

HY-12848B

SAG hydrochloride Maximum Cited Publications 18 Publications Verification	Smo	Cancer
SAG hydrochloride is a potent Smoothened (Smo) receptor agonist (EC₅₀=3 nM; K_d=59 nM). SAG hydrochloride activates the Hedgehog signaling pathway and counteracts Cyclopamine (HY-17024) inhibition of Smo .

HY-N0608

Myrislignan	NF-κB	Inflammation/Immunology
Myrislignan, a lignan isolated from Myristica fragrans Houtt, possesses anti-inflammatory activities. Myrislignan attenuates LPS-induced inflammation reaction in murine macrophage cells through inhibition of NF-kB signalling pathway activation .

HY-12848C

SAG dihydrochloride Maximum Cited Publications 18 Publications Verification	Smo	Cancer
SAG dihydrochloride is a potent Smoothened (Smo) receptor agonist (EC₅₀=3 nM; K_d=59 nM). SAG dihydrochloride activates the Hedgehog signaling pathway and counteracts Cyclopamine (HY-17024) inhibition of Smo .

HY-P99895

Rulonilimab	PD-1/PD-L1	Inflammation/Immunology Cancer
Rulonilimab is a human IgG1 monoclonal antibody against PD-1 that targets, binds and inhibits PD-1 and its downstream signalling pathways with potential immune checkpoint inhibition and anti-tumour activity .

HY-P99818

Ramatercept	TGF-β Receptor	Metabolic Disease
Ramatercept is a soluble ActRIIB receptor and can be used as a soluble activin receptor 2 (ACVR2) antagonist. Ramatercept inhibits the signal pathway of muscle growth inhibition and has potential application in muscle atrophy .

HY-N1513

Ganoderic acid H	AP-1 NF-κB	Cancer
Ganoderic acid H is a lanostane-type triterpene isolated from Ganoderma lucidum. Ganoderic acid H suppresses growth and invasive behavior of breast cancer cells through the inhibition of transcription factors AP-1 and NF-kappaB signaling .

HY-N8107

Matairesinol monoglucoside	Others	Others
Matairesinol monoglucoside, a lignan compound, exhibits low activity on IFN-γ/STAT1 and IL-6/STAT3 signaling pathways with inhibition ratio of 5.8% and 7.0%, respectively .

HY-N6036

Ganoderic acid F 1 Publications Verification	Others	Cancer
Ganoderic acid F is a ganoderic acid. Ganoderic acid F exhibits antitumor and antimetastatic activities through inhibition of angiogenesis and alteration of proteins involving cell proliferation and/or cell death, carcinogenesis, oxidative stress, calcium signaling, and endoplasmic reticulum stress .

HY-N0608A

(Rac)-Myrislignan	NF-κB	Inflammation/Immunology
(Rac)-Myrislignan is the racemate of Myrislignan. Myrislignan, a lignan isolated from Myristica fragrans Houtt, possesses anti-inflammatory activities. Myrislignan attenuates LPS-induced inflammation reaction in murine macrophage cells through inhibition of NF-kB signalling pathway activation .

HY-151931

JA-ACC Jasmonyl-ACC	Others	Metabolic Disease
JA-ACC (Jasmonyl-ACC) is a derivative of 1-aminocyclopropane-1-carboxylic acid (ACC). ACC is the direct precursor of the plant hormone ethylene. JA-ACC inhibits root growth in Arabidopsis and the inhibition is independent of jasmonic acid (JA) signaling .

HY-145267

OM-153	PARP Wnt	Cancer
OM-153 is a potent and orally active tankyrase inhibitor with IC₅₀s of 13 nM and 2 nM for tankyrase 1 and tankyrase 2 (TNKS1/2), respectively. OM-153 inhibits luciferase-based Wnt/β-catenin signaling reporter activity with an IC₅₀ value of 0.63 nM. OM-153 shows inhibition of Wnt/β-catenin signaling and proliferation in COLO 320DM .

HY-15185

Nirogacestat 5+ Cited Publications PF-3084014; PF-03084014	γ-secretase Apoptosis	Cancer
Nirogacestat (PF-3084014) is a reversible, orally bioavailable, noncompetitive, and selective γ-secretase inhibitor with an IC₅₀ of 6.2 nM. Inhibition of Notch signaling by Nirogacestat while minimizing gastrointestinal toxicity presents a promising approach for research of Notch receptor-dependent cancers .

HY-162257

BTK-IN-34	Btk	Cancer
BTK-IN-34 (compound 9h) is a selective BTK inhibitor. BTK-IN-34 shows antiproliferative activity in RAMOS cells through selective inhibition of pBTK (Tyr223) without affecting Lyn and Syk, upstream proteins in the BCR signaling pathway .

HY-145721

Mongersen GED-0301	TGF-beta/Smad	Inflammation/Immunology
Mongersen (GED-0301) is a specific and orally active SMAD7 antisense oligonucleotide. Mongersen restores TGF-β1 activity leading to inhibition of inflammatory signals. Mongersen can attenuate Crohn's disease-like experimental colitis in mice .

HY-12848A

(Rac)-SAG	Smo	Cancer
(Rac)-SAG is an isoform of SAG (HY-12848). SAG is a potent Smoothened (Smo) receptor agonist (EC₅₀=3 nM; K_d=59 nM). SAG activates the Hedgehog signaling pathway and counteracts Cyclopamine (HY-17024) inhibition of Smo .

HY-P5819

xStAx-VHLL	Wnt APC PROTACs β-catenin	Cancer
xStAx-VHLL is a PROTAC β-catenin degrader that manifests strong inhibition of Wnt signaling and sustains degradation of β-catenin in cancer cells and the intestinal organoids derived from wild-type and APC ^–/– mice. xStAx-VHLL can be used as a promising anticancer agent .

HY-141543

YW2065	β-catenin	Cancer
YW2065 is an Axin-1 stabilizer. Axin-1 is a scaffolding protein that regulates proteasome degradation of β-catenin. YW2065 exhibits anti-colorectal cancer effects via dual activities of wnt/β-catenin signaling inhibition and AMPK activation .

HY-15185B

Nirogacestat dihydrobromide 5+ Cited Publications PF-3084014 dihydrobromide; PF-03084014 dihydrobromide	γ-secretase Apoptosis	Cancer
Nirogacestat dihydrobromide (PF-3084014 dihydrobromide) is a reversible, orally bioavailable, noncompetitive, and selective γ-secretase inhibitor with an IC₅₀ of 6.2 nM. Inhibition of Notch signaling by Nirogacestat dihydrobromide while minimizing gastrointestinal toxicity presents a promising approach for research of Notch receptor-dependent cancers .

HY-147566

ATR-IN-14	ATM/ATR	Cancer
ATR-IN-14 (compound 1) is a potent ATR kinase inhibitor. ATR-IN-14 inhibits ATR signaling pathways downstream CHKI protein phosphorylation, with inhibition of 98.03% at 25 nM. ATR-IN-14 shows good anticancer activity in LoVo cells, with an IC₅₀ of 64 nM .

HY-117616

Laurotetanine (+)-Laurotetanine	NF-κB	Cancer
Laurotetanine ((+)-Laurotetanine) is an potent and orally active isoquinoline alkaloid and could be extracted from the roots of Litsea cubeba (Lour.) Pers. Laurotetanine exerts an anti-asthmatic effect by inhibition of IgE, histamine, and inflammatory reactions via down-regulating MUC5AC and NF-κB signaling pathways .

HY-121222

alpha-Bisabolol	PI3K Apoptosis	Cancer
alpha-Bisabolol, an orally active sesquiterpene alcohol, induces cell cycle arrest, mitochondrial apoptosis and inhibition of PI3K/Akt signalling pathways. alpha-Bisabolol exerts a protective action against Cisplatin (HY-17394)-induced nephrotoxicity by mitigating inflammation and oxidative stress through the inhibition of NFκB activation. alpha-Bisabolol exhibits anti-inflammatory, analgesic, antibiotic and anticancer activities .

HY-N1326

Santamarine Santamarin; Balchanin	Keap1-Nrf2	Inflammation/Immunology
Santamarine (Santamarin), a sesquiterpene lactone, increases HO-1 expression through Nrf2 translocation and suppresses NO, PGE2, TNF-α, and IL-1β production through inhibition of NF-κB translocation in LPS-induced macrophages. Santamarine shows anti-photoaging properties via inhibition of MAPK/AP-1 and stimulation of TGF-β/Smad signaling in UVA-irradiated human dermal fibroblasts (HDFs). Antioxidant activities .

HY-N0781

Linderalactone 1 Publications Verification	Apoptosis	Cancer
Linderalactone is an important sesquiterpene lactone isolated from Lindera aggregata. Linderalactone inhibits cancer growth by modulating the expression of apoptosis-related proteins and inhibition of JAK/STAT signalling pathway. Linderalactone also inhibits the proliferation of the lung cancer A-549 cells with an IC₅₀ of 15 µM .

HY-18959

CWP232228 4 Publications Verification
CWP232228, a highly potent selective Wnt/β-catenin signaling inhibitor, antagonizes binding of β-catenin to T-cell factor (TCF) in the nucleus. CWP232228 suppresses tumor formation and metastasis without toxicity through the inhibition of the growth of breast and liver cancer stem cells (CSCs) .

HY-144127

AR antagonist 3	Androgen Receptor	Cancer
AR antagonist 3 is a potent and selective androgen receptor (AR) antagonist with an IC₅₀ of 0.47 µM. AR antagonist 3 exhibits a dose-dependent decrease of the FRET signal (IC₅₀= 18.05 μM). AR antagonist 3 shows effective inhibition on tumor growth when administered intratumorally .

HY-126397

MnTBAP chloride 1 Publications Verification	NF-κB	Inflammation/Immunology
MnTBAP chloride is a superoxide dismutase (SOD) mimetic and peroxynitrite scavenger. MnTBAP chloride is a manganic porphyrin complex and has anti-oxidative property. MnTBAP chloride mediates anti-inflammatory effects through upregulation of BMPR-II and inhibition of the NFκB signaling. MnTBAP chloride has the potential for the fibrotic response in chronic kidney diseases (CKDs) research .

HY-132310

MAGL-IN-4	MAGL	Neurological Disease
MAGL-IN-4 is an orally active, selective and reversible monoacylglycerol lipase (MAGL) inhibitor with an IC₅₀ of 6.2 nM. MAGL-IN-4 can penetrate the blood-brain barrier (BBB). MAGL-IN-4 enhances endocannabinoid signaling mostly by the increase in the level of 2-AG via selective MAGL inhibition in the brain .

HY-103224

PIT-1	PI3K	Cancer
PIT-1 is a selective PIP3 (phosphatidylinositol 3,4,5-trisphosphate) antagonist. PIT-1 inhibits cancer cell survival and induces apoptosis by inhibition of PIP3 dependent PI3K / Akt signaling. PIT-1 exhibits antitumor activity in vivo .

HY-13968

JW 55 2 Publications Verification	PARP	Cancer
JW 55 is a potent and selective β-catenin signaling pathway inhibitor, which functions via inhibition of the PARP domain of tankyrase 1 and tankyrase 2 (TNKS1/2). JW 55 decreases auto-PARsylation of TNKS1/2 in vitro with IC₅₀s of 1.9 μM and 830 nM respectively.

HY-153542

AP-C6	Others	Others
AP-C6 is a potent inhibitor of guanosine 3′,5′-cyclic monophosphate (cGMP)-dependent protein kinase II (cGKII) with a pIC₅₀ of 6.5. AP-C6 concentration-dependently inhibits human cGKII activity in vitro. AP-C6 potentiate cAMP signaling by PDE inhibition .

HY-N6246

Asperulosidic Acid	NF-κB ERK	Inflammation/Immunology Cancer
Asperulosidic Acid (ASPA), a bioactive iridoid glycoside, is extracted from the herbs of Hedyotis diffusa Willd. Asperulosidic Acid (ASPA) has anti-tumor, anti-oxidant, and anti-inflammatory activities . ASPA is related to the inhibition of inflammatory cytokines (TNF-α, IL-6) and mediators via suppression of the NF-κB and mitogen-activated protein kinase (MAPK) signaling pathways .

HY-P2230

Angstrom6 A6 Peptide	PAI-1	Cancer
Angstrom6 (A6 Peptide) is an 8 amino-acid peptide derived from single-chain urokinase plasminogen activator (scuPA) and interferes with the uPA/uPAR cascade and abrogates downstream effects. Angstrom6 binds to CD44 resulting in the inhibition of migration, invasion, and metastasis of tumor cells, and the modulation of CD44-mediated cell signaling .

HY-111557

YM-254890 5+ Cited Publications	P2Y Receptor	Cardiovascular Disease
YM-254890 is a selective G_αq/11 protein inhibitor isolated from Chromobacterium sp. YM-254890 shows no inhibition of other G protein subtypes. YM-254890 inhibits platelet aggregation induced by ADP by blocking the P2Y₁ signal transduction pathway, with an IC₅₀ value below 0.6 μM .

HY-150744

ODN 24888	Toll-like Receptor (TLR)	Inflammation/Immunology
ODN 24888 is an guanine-modified inhibitory oligonucleotides (INH-ODN), shows potent inhibition on TLR7/TLR9-mediated signaling. ODN 24888 impairs IFN-α level and NF-κB activation, inhibits IL-6 release. ODN 24888 involves in immune and inflammatory responses, can be used as a vaccine adjuvant .

HY-143321

STING agonist-13	STING	Cancer
STING agonist-13 is a stimulator of interferon genes (STING) agonist, for cancer immunity via STING-mediated immune activation. STING agonist-13 can stimulate STING downstream signaling and promoting type I interferon immune responses. STING agonist-13 significantly decreases tumor volume and shows immunological memory-derived cancer inhibition .

Cat. No.	Product Name

HY-L015

PI3K/Akt/mTOR Compound Library

575 compounds

The PI3K/Akt/mTOR pathway controls many cellular processes that are important for the formation and progression of cancer, including apoptosis, transcription, translation, metabolism, angiogenesis, and cell cycle progression. Every major node of this signaling network is activated in a wide range of human tumors. Mechanisms for the pathway activation include activation of receptor tyrosine kinases (RTKs) upstream of PI3K, mutation or amplification of PIK3CA encoding p110α catalytic subunit of PI3K, mutation or loss of PTEN tumor suppressor gene, and mutation or amplification of Akt1. Once the pathway is activated, signaling through Akt can stimulate a series of substrates including mTOR which is involved in protein synthesis. Thus, inhibition of this pathway is an attractive concept for cancer prevention and/or therapy. Currently some mTOR inhibitors are approved for several indications, and there are several novel PI3K/Akt/mTOR inhibitors in clinical trials.

MCE owns a unique collection of 575 compounds that can be used for PI3K/Akt/mTOR pathway research. PI3K/Akt/mTOR Compound Library also acts as a useful tool for anti-cancer drug discovery.

HY-L089

Mitochondria-Targeted Compound Library

894 compounds

Mitochondria plays an important role in many vital processes in cells, including energy production, fatty-acid oxidation and the Tricarboxylic Acid (TCA) cycle, calcium signaling, permeability transition, apoptosis and heat production. At present, it is recognized that many diseases are associated with impaired mitochondrial function, such as increased accumulation of ROS and decreased OXPHOS and ATP production. Mitochondria are recognized as one of the most important targets for new drug design in cancer, cardiovascular, and neurological diseases, etc. Some small molecule drugs or biologics can act on mitochondria through various pathways, including ETC inhibition, OXPHOS uncoupling, mitochondrial Ca²⁺ modulation, and control of oxidative stress via decrease or increase of mitochondrial ROS accumulation.

MCE supplies a unique collection of 894 mitochondria-targeted compound that mainly targeting Mitochondrial Metabolism, ATP Synthase, Mitophagy, Reactive Oxygen Species, etc. MCE Mitochondria-Targeted Compound Library is a useful tool for mitochondria-targeted drug discovery and related research.

Cat. No.	Product Name	Target	Research Area

HY-P99895

Rulonilimab	PD-1/PD-L1	Inflammation/Immunology Cancer
Rulonilimab is a human IgG1 monoclonal antibody against PD-1 that targets, binds and inhibits PD-1 and its downstream signalling pathways with potential immune checkpoint inhibition and anti-tumour activity .

HY-P99590

Sotatercept ACE-011	TGF-β Receptor	Inflammation/Immunology Cancer
Sotatercept (ACE-011) is a soluble activin receptor 2A (ACVR2A) type IgG Fc fusion protein. Sotatercept combines activin and growth differentiation factor to try to restore the balance between growth promotion and growth inhibition signal pathways. Sotatercept has potential application in pulmonary arterial hypertension, anemia, bone loss, erythropoiesis, multiple myeloma (MM) osteolytic lesions .

HY-P99361

Enavatuzumab PDL192; ABT-361; Anti-TNFRSF12A/TWEAKR/CD266 Reference Antibody (enavatuzumab)	TNF Receptor	Cancer
Enavatuzumab (PDL192; ABT-361) is a humanized IgG1 monoclonal antibody targeting the receptor of TNF-like weak inducer of apoptosis (TWEAK). TWEAK (Fn14; TNFRSF12A), the natural ligand of the TWEAK receptor (TweakR), stimulates multiple cellular responses. Enavatuzumab induces tumor growth inhibition through direct TweakR signaling and antibody dependent cell-mediated cytotoxicity (ADCC). Enavatuzumab can actively recruits and activates myeloid effectors to kill tumor cells. Enavatuzumab inhibits the growth of various human TweakR-positive cancer cell lines and xenografts in vitro and in vivo .

HY-P99818

Ramatercept	TGF-β Receptor	Metabolic Disease
Ramatercept is a soluble ActRIIB receptor and can be used as a soluble activin receptor 2 (ACVR2) antagonist. Ramatercept inhibits the signal pathway of muscle growth inhibition and has potential application in muscle atrophy .

HY-P99925

Enoticumab REGN421	Notch	Metabolic Disease Cancer
Enoticumab (REGN421, SAR153192) is an IgG1κ antibody targeting human Dll4. DLL4 is a ligand of the Notch signaling pathway and regulates fatty acid uptake through non-transcriptional regulation of macropinocytosis-dependent long-chain fatty acid uptake. Specific in vivo activity of Enoticumab in an ovarian xenograft model. EGN421 (2.5 mg/kg once weekly) resulted in 86% and 83% tumor growth inhibition in mouse subcutaneous TOV-112D or intraperitoneal A2780 human tumor xenograft models, respectively .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks